Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis

BACKGROUND: Novel disease-modifying antirheumatic drugs (DMARDs) can slow disease progression among patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA); however, some health plans require prior authorization (PA) or step therapy for access to treatments. OBJECTIVES: This retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Boytsov, Natalie, Zhang, Xiang, Evans, Kristin A., Johnson, Barbara H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018889/
https://www.ncbi.nlm.nih.gov/pubmed/31177506
http://dx.doi.org/10.1007/s41669-019-0152-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018889/
https://www.ncbi.nlm.nih.gov/pubmed/31177506
http://dx.doi.org/10.1007/s41669-019-0152-1

Ejemplares similares